On September 12, the first commercialized drug of Sinotau, adenosine Injection(with Chinese trade name 歐達樂?, 20ml:60mg), was supplied to major hospitals nationwide, and formally entered the domestic clinical application.

Adenosine injection is the classic drug of choice for drug loading, which was approved by the National Drug Administration (NMPA) for marketing license in January this year. It is the only loading drug in China with two indications: for myocardial perfusion imaging and echocardiographic drug loading test to assist in the diagnosis of coronary artery disease, and it has provided a new choice of non-invasive myocardial ischemia examination for patients with coronary artery disease in China.

Adenosine has high sensitivity and specificity, good safety, and both domestic and international guideline consensus recommend adenosine as the preferred loading agent.

On August 10, adenosine injection successfully passed the GMP compliance inspection; on September 12, under the full cooperation with our partner Shandong Qidu Pharmaceutical Co., Ltd, the first batch ofadenosine injection successfully completed the product out of the warehouse, which will be sent to all parts of the country, marking the successful opening of the road to commercialization of adenosine injection, and more patients with coronary heart disease will be benefited as a result.

Mr. Xinsheng Xu, Chairman of Sinotau, said, “We are very pleased that Sinotau’s first commercialized drug, adenosine Injection(with Chinese trade name 歐達樂? ), has completed its first batch of logistics and distribution, and we would like to thank all the colleagues who have helped adenosine Injection to enter the domestic clinical application. In the future, the company will continue to launch more precision diagnostic and targeted therapeutic nuclear drugs with good efficacy, high safety and accessibility to further meet the unmet clinical needs of patients.”